Layout Table~~~~3039~3039~~

The World Schizophrenia Market 2005-2010~
Published by Visiongain, August 2005

The schizophrenia world market generated total revenues of nearly $12 billion in 2004. The market is growing now. Are you capitalising on this market? Did you benefit from the strong growth in 2003 and 2004? With almost all the leading drugs also approved for treating aspects of bipolar disorder, the opportunities for drugs in this market are increasing rapidly. Dementia, autism, aggression, post-traumatic stress disorder and severe depression - the unapproved (off-label) uses for some of the drugs offer improved sales options. Ensure you benefit today by reading visiongain's unique report.

~Published by Visiongain, August 2005

The schizophrenia world market generated total revenues of nearly $12 billion in 2004. The market is growing now. Are you capitalising on this market? Did you benefit from the strong growth in 2003 and 2004? With almost all the leading drugs also approved for treating aspects of bipolar disorder, the opportunities for drugs in this market are increasing rapidly. Dementia, autism, aggression, post-traumatic stress disorder and severe depression - the unapproved (off-label) uses for some of the drugs offer improved sales options. Ensure you benefit today by reading visiongain's unique report.

This market report delivers to you exactly how schizophrenia treatments will develop this decade. You will receive analytical forecasts of the market from 2005 to 2010. This executive report presents you with financial forecasting, SWOT analysis and perceptual mapping applied specifically to the schizophrenia drug market.

In particular, the report concentrates on the following areas:

• The current state of the market for atypical antipsychotic drugs in the treatment of schizophrenia
• Drivers and opportunities in the schizophrenia market
• Restraints and threats in the schizophrenia market
• How the schizophrenia market is likely to grow between 2005 and 2010
• Prospects for the current market leading drugs between 2005 and 2010
• The potential for generics manufacturers to penetrate the market further
• A breakdown of the schizophrenia market by country and region
• A discussion of unmet needs in the schizophrenia market
• Detailed information on pipeline products and line extensions in this market, with an analysis of the prospects for those agents
• The schizophrenia market dominated by 6 drugs marketed by 8 companies:

1. Eli Lilly's Zyprexa
2. Johnson & Johnson's Risperdal
3. AstraZeneca and Fujisawa Pharmaceutical's Seroquel
4. Bristol-Myers Squibb and Otsuka Pharmaceutical's Abilify
5. Pfizer's Geodon
6. Novartis' Clozaril/Leponex

With continued prospects for high revenue generation and market growth, this market demands your attention. Nevertheless, the schizophrenia market is facing great challenges in terms of clinical performance, competition, regulatory restraints and legal challenges. Given the complexity of schizophrenia, continued investment in research and development of improved treatments is required, as well as research into the causes and mechanisms of the disorder - this is costly and time-consuming. However recent developments in both the pharmaceutical industry and the public sector provide scope for optimism - understand these crucial issues today.

Why You Should Buy This Report?

Visiongain's report pays particular attention to revenues, growth rates and market shares for schizophrenia treatments. It discusses the forces that influence the schizophrenia market, especially its competitive characteristics, drivers and restraints. With unique insight the report offers the strengths, weaknesses, opportunities and threats of individual products.

A key chapter forecasts the performance of the current leading drugs until 2010. Visiongain's in-house analytical assessment of future revenues, growth rates and relative market shares are available to you in one easy to read format. Various quantitative and qualitative methods are used, with the relevant issues discussed fully for you.

Plus, the report also includes a breakdown of the world market for atypical antipsychotic drugs into countries and regions, including relevant statistics on spending across the world. Importantly, the report discusses pipeline developments for treating schizophrenia comprehensively in the future. The market appears to be entering an exciting new phase, with both established market leaders and potential new entrants having products in mid-to-late stage development - you should be part of this market.


Table of Contents

~The World Schizophrenia Market 2005-2010 (Single user License PDF)|968|The World Schizophrenia Market 2005-2010 (Department License PDF)|969|The World Schizophrenia Market 2005-2010 (Company wide license PDF)|970|~3039~3043~~